Seroxat and the suppression of clinical trial data: regulatory failure and the uses of legal ambiguity
Authors:
- 30 January 2009
- journal article
- Published by BMJ in Journal of Medical Ethics
- Vol. 35 (2) , 107-112
Abstract
This article critically evaluates the Medicines and Healthcare products Regulatory Agency’s announcement, in March 2008, that GlaxoSmithKline would not face prosecution for deliberately withholding trial data, which revealed not only that Seroxat was ineffective at treating childhood depression but also that it increased the risk of suicidal behaviour in this patient group. The decision not to prosecute followed a four and a half year investigation and was taken on the grounds that the law at the relevant time was insufficiently clear. This article assesses the existence of significant gaps in the duty of candour which had been assumed to exist between drugs companies and the regulator, and reflects upon what this episode tells us about the robustness, or otherwise, of the UK’s regulation of medicines.Keywords
This publication has 13 references indexed in Scilit:
- From drug crises to regulatory change: The mediation of expertiseHealth, Risk & Society, 2008
- Organized Uncertainty2007
- Interpellative Sociology of Pharmaceuticals: Problems and Challenges for Innovation and Regulation in the 21st CenturyTechnology Analysis & Strategic Management, 2007
- On the will to ignorance in bureaucracyEconomy and Society, 2007
- Truth, Disclosure and the Influence of Industry on the Development of NICE Guidelines: An Interview with Tim KendallBioSocieties, 2007
- Education and debateMaking regulation responsive to commercial interests: streamlining drug industry watchdogsCommentary: Concern over drug industry's influence on regulatory policy in EuropeCommentary: Much ado about a good thingCommentary: The freedom of informed choiceBMJ, 2002
- Transnational industrial power, the medical profession and the regulatory state: adverse drug reactions and the crisis over the safety of Halcion in the Netherlands and the UKSocial Science & Medicine, 2002
- Vaccines and medicines for the world's poorestBMJ, 2000
- Harmonising and competing for medicines regulation: how healthy are the European Union's systems of drug approval?Social Science & Medicine, 1999
- Distributing the Benefit of the Doubt: Scientists, Regulators, and Drug SafetyScience, Technology, & Human Values, 1994